S100A8 and breast carcinoma: To evaluate the high expression IL-1β, CXCL1, CCL2, S100A8, VEGF and IL8 as surrogate biomarker for aggressive breast cancers (e.g., IRISOE TNBC tumors), meta-analysis based biomarker assessment using the online tool Kaplan Meier Plotter (http://kmplot.com/analysis [52]) was performed.